A Phase II Study to Evaluate the Safety and Efficacy of Defibrotide in Sickle Cell Disease-Related Acute Chest Syndrome (IND 127812)

Authors

E Schaefer
T Kanarfogel
J C. Hochberg, New York Medical CollegeFollow
E Thatcher
L Klejmont, New York Medical College
Y Y. Chu, New York Medical CollegeFollow
Q H. Shi, New York Medical College
A J. Dozer, New York Medical College
D Friedman, New York Medical College
H Mahanti
E Morris
S Fabricatore
J DeFresne
K R. Cooke
M S. Cairo, New York Medical CollegeFollow

Author Type(s)

Faculty, Resident/Fellow

Document Type

Abstract

Publication Date

11-15-2022

DOI

10.1182/blood-2022-168299

Journal Title

Blood

Department

Pediatrics

Second Department

Medicine

Third Department

Public Health

Recommended Citation

Schaefer, E., Kanarfogel, T., Hochberg, J. C., Thatcher, E., Klejmont, L., Chu, Y. Y., Shi, Q. H., Dozer, A. J., Friedman, D., Mahanti, H., Morris, E., Fabricatore, S., DeFresne, J., Cooke, K. R., & Cairo, M. S. (2022). A Phase II Study to Evaluate the Safety and Efficacy of Defibrotide in Sickle Cell Disease-Related Acute Chest Syndrome (IND 127812). Blood, 140, 2532-2534. https://doi.org/10.1182/blood-2022-168299